Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0035 in Adult Patients With Wolfram Syndrome
NCT05676034Phase 2Active, not recruiting
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium phenylbutyrate in Wolfram syndrome, sponsored by Amylyx Pharmaceuticals. Started Mar 2023; status: active, not recruiting.
02
Drugs
sodium phenylbutyrate
03
Conditions
Wolfram syndrome
Beyond the preview
Go deeper on NCT05676034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676034.